Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rovalpituzumab Tesirine |
Synonyms | |
Therapy Description |
Rovalpituzumab Tesirine (Rova-T) is an antibody drug conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rovalpituzumab Tesirine | Rova-T|SC16LD6.5 | Rovalpituzumab Tesirine (Rova-T) is an antibody drug conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02819999 | Phase I | Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02674568 | Phase II | Rovalpituzumab Tesirine | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) | Completed | 0 | |
NCT03061812 | Phase III | Rovalpituzumab Tesirine Topotecan | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) | Completed | USA | TUR | SWE | ROU | POL | NLD | LVA | ITA | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT02709889 | Phase Ib/II | Rovalpituzumab Tesirine | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Terminated | USA | 0 |
NCT03543358 | Phase II | Rovalpituzumab Tesirine | A Long-Term Study of Rovalpituzumab Tesirine | Completed | USA | 0 |
NCT02874664 | Phase I | Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | Completed | USA | CAN | 0 |